查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951167

DNA甲基化檢測技術市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、應用、產品、最終用戶、地區和競爭格局分類，2021-2031年）

DNA Methylation Detection Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By Product, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球DNA甲基化檢測技術市場預計將從2025年的42.2億美元成長到2031年的84.1億美元，複合年成長率達到12.18%。

這項技術涵蓋了用於識別和測量表觀遺傳修飾的分析方法，特別是DNA分子上甲基化的修飾，這種修飾能夠在不改變鹼基序列的情況下調控基因表現。該市場成長的主要驅動力是腫瘤和慢性疾病在全球範圍內日益成長的影響，從而產生了對可靠生物標記的迫切需求，以支持早期檢測和精準醫療。根據美國癌症協會預測，2024年美國預計將新增約2,001,140例癌症病例，凸顯了此類診斷能力的重要性。

市場概覽
預測期 2027-2031
市場規模：2025年 42.2億美元
市場規模：2031年 84.1億美元
複合年成長率：2026-2031年 12.18%
成長最快的細分市場 診斷程序
最大的市場 北美洲

非侵入性液態生物檢體技術的日益普及進一步推動了這一領域的發展。該技術利用甲基化模式以極高的靈敏度檢測循環腫瘤DNA，使臨床醫生能夠比傳統組織切片檢查更有效地制定個人化治療方案。然而，市場面臨一個重大障礙：高通量定序設備成本高昂，這可能會限制其廣泛應用並阻礙市場整體擴張。

市場促進因素

液態生物檢體在非侵入性診斷領域，尤其是在癌症早期檢測和監測方面的日益普及，正成為推動市場成長的主要動力。這些檢測利用甲基化模式高特異性地識別循環腫瘤DNA，為患者提供了比侵入性組織取樣更便捷的選擇。主要企業正經歷這些基於甲基化的篩檢工具的顯著商業性應用，不僅提升了其臨床效用，也推動了市場滲透。例如，Exact Sciences在其2024年2月發布的「2023年第四季度收益報告」中指出，篩檢業務（包括基於甲基化的Cologuard檢測）在2023年全年的收入達到18.6億美元，這表明表觀遺傳生物標記在常規篩檢和預防性醫療保健模式中的重要性日益凸顯。

同時，政府和私人機構對表觀基因學研究投入的增加正在加速創新並提高其可及性。聯邦預算優先考慮依賴先進基因組分析來降低死亡率的腫瘤學舉措，從而創造有利於產品快速開發的環境。 2024年4月，美國癌症研究協會（AACR）報告稱，美國國家癌症研究所（NCI）已獲得72億美元的2024會計年度撥款，用於支持關鍵研究計畫。這筆資金將用於開發利用次世代定序平台和DNA甲基化技術的精準腫瘤學工具。作為這一整體市場成長動能的例證，Guardant Health公司報告稱，其2024年第三季營收達1.915億美元，年增34%。

市場挑戰

高通量定序設備所需的巨額資本和營運成本是全球DNA甲基化檢測技術市場擴張的主要障礙。這些先進的平台對於以所需靈敏度識別甲基化模式至關重要，但其高昂的實施成本給小規模臨床檢查室和研究機構的預算帶來了沉重負擔。這種經濟負擔不僅限於初始購買成本，還包括昂貴的試劑、專業的生物資訊基礎設施以及解讀複雜表觀遺傳數據的高技能人員。因此，這種高成本結構限制了該技術在價格敏感地區和社區醫院的應用，使其主要局限於資金雄厚的學術機構和參考實驗室。

這些財務障礙迫使實驗室縮減或取消診斷服務，從而抑制了市場成長。據美國診斷和實驗室醫學學會 (ADLM) 稱，到 2024 年，約 48% 的受訪臨床檢查室預計將被迫停止某些檢查室自主開發的檢測服務，原因是維持合規性和檢驗複雜診斷流程所帶來的過重財務和資源負擔。這一趨勢凸顯了購置和維護先進基因組學設備成本的不斷攀升如何有效地減少了市場參與企業的數量，並阻礙了基於甲基化的診斷技術的廣泛應用。

市場趨勢

第三代定序的引進正在革新市場，它無需進行有害的亞硫酸氫鹽轉化即可直接檢測甲基化。與傳統的化學修飾DNA並降低樣本品質的方法不同，奈米孔定序能夠讀取表觀遺傳修飾的天然狀態，並在長讀長資料中區分5-甲基胞嘧啶和5-羥甲基胞嘧啶。這項技術變革顯著提高了數據準確性，簡化了高通量實驗室的工作流程，並加速了天然定序平台相對於複雜化學轉換通訊協定的普及。牛津奈米孔技術公司（Oxford Nanopore Technologies plc）於2025年3月發布的「截至2024年12月31日的年度表現」凸顯了市場對這種先進直接定序技術的需求。業績顯示，其支持高功率天然甲基化分析的PromethION產品線營收成長55.8%，達到7,590萬英鎊。

同時，人工智慧 (AI) 與機器學習的融合正成為解決海量表觀遺傳資料集分析複雜性的關鍵趨勢。由於甲基化譜分析會產生高維度數據，人工智慧演算法正被用於識別新的生物標記並預測患者預後，其準確性已超越人工生物資訊流程。臨床醫療機構正迅速將這項計算技術的進步轉化為商業價值，他們希望透過整合基因組學和臨床模式的智慧診斷來實現精準醫療。為了反映人工智慧驅動的基因組學領域的成長，Tempus AI 在 2025 年 2 月發布的「2024 年第四季及全年財務表現」報告中指出，其基因組學部門（該部門利用人工智慧驅動的精準醫療模型）2024 年全年的收入達到 4.517 億美元。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球DNA甲基化檢測技術市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 透過技術（聚合酵素鏈鎖反應（PCR）、微陣列、定序、其他技術）
    • 按應用領域（轉化研究、診斷程序）
    • 依產品分類（耗材、設備、軟體）
    • 按最終用戶分類（合約研究組織 (CRO)、研究/學術機構、生物製藥/生物技術公司、其他最終用戶）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美DNA甲基化檢測技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲DNA甲基化檢測技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區DNA甲基化檢測技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲DNA甲基化檢測技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美DNA甲基化檢測技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球DNA甲基化檢測技術市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies, Inc.
  • Abcam Limited
  • Bio-Rad Laboratories, Inc
  • Illumina, Inc
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Pacific Biosciences of California, Inc.
  • Merck KGaA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24116

The Global DNA Methylation Detection Technology Market is projected to expand from USD 4.22 Billion in 2025 to USD 8.41 Billion by 2031, achieving a compound annual growth rate (CAGR) of 12.18%. This technology involves analytical methods designed to identify and measure epigenetic modifications, specifically where methyl groups attach to DNA molecules to regulate gene expression without changing the underlying sequence. The market is largely propelled by the rising global impact of oncology and chronic diseases, which generates an urgent demand for robust biomarkers to support early detection and precision medicine. According to the American Cancer Society, approximately 2,001,140 new cancer cases are expected in the United States in 2024, underscoring the critical need for these diagnostic capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.22 Billion
Market Size 2031USD 8.41 Billion
CAGR 2026-203112.18%
Fastest Growing SegmentDiagnostic Procedure
Largest MarketNorth America

This sector is further bolstered by the growing utilization of noninvasive liquid biopsy applications, which leverage methylation patterns to detect circulating tumor DNA with exceptional sensitivity. These technological advancements enable clinicians to customize therapeutic strategies more effectively than traditional tissue biopsies allow. However, the market encounters a major obstacle due to the significant costs involved with high-throughput sequencing instruments, which may restrict broad implementation and hinder overall market expansion.

Market Driver

The rising adoption of liquid biopsy for non-invasive diagnostics serves as a major catalyst for growth, particularly regarding early cancer detection and monitoring. These tests employ methylation patterns to identify circulating tumor DNA with high specificity, providing a patient-friendly alternative to invasive tissue sampling. Leading diagnostic companies are experiencing significant commercial uptake of these methylation-based screening tools, confirming their clinical utility and driving market penetration. For example, Exact Sciences noted in their 'Fourth Quarter 2023 Earnings Report' in February 2024 that screening revenue, including the methylation-based Cologuard test, hit $1.86 billion for the full year 2023, reflecting a growing dependence on epigenetic biomarkers for routine screening and preventative healthcare models.

Concurrently, the expansion of government and private funding for epigenomics research is accelerating technological innovation and accessibility. Federal budgets are increasingly prioritizing oncology initiatives that rely on advanced genomic analysis to lower mortality rates, fostering an environment conducive to rapid product development. The American Association for Cancer Research reported in April 2024 that the National Cancer Institute (NCI) received a $7.2 billion appropriation for fiscal year 2024 to support critical research programs. This financial influx supports the development of next-generation sequencing platforms and precision oncology tools utilizing DNA methylation. Illustrating this broader market momentum, Guardant Health reported a 34% revenue increase to $191.5 million in the third quarter of 2024 compared to the previous year.

Market Challenge

The substantial capital and operational expenditures required for high-throughput sequencing instruments constitute a primary barrier to the expansion of the Global DNA Methylation Detection Technology Market. These sophisticated platforms, which are essential for identifying methylation patterns with the necessary sensitivity, command high acquisition prices that strain the budgets of smaller clinical laboratories and research institutions. The financial burden extends beyond the initial purchase to include costly reagents, specialized bioinformatics infrastructure, and the need for highly skilled personnel to interpret complex epigenetic data. Consequently, this high cost structure limits the technology's penetration in price-sensitive regions and community hospital settings, restricting its availability largely to well-funded academic centers and reference laboratories.

This financial impediment directly forces testing facilities to scale back or abandon their diagnostic offerings, thereby stalling market growth. According to the Association for Diagnostics & Laboratory Medicine, in 2024, approximately 48% of surveyed clinical laboratories indicated they would be compelled to discontinue specific laboratory-developed testing services due to the prohibitive financial and resource demands associated with maintaining compliance and validation for such complex diagnostic workflows. This trend highlights how escalating costs associated with deploying and maintaining advanced genomic instrumentation effectively reduce the number of active market participants, thereby hampering the widespread adoption of methylation-based diagnostics.

Market Trends

The implementation of third-generation sequencing is revolutionizing the market by enabling direct methylation detection without the need for damaging bisulfite conversion. Unlike traditional methods that chemically alter DNA and degrade sample quality, nanopore sequencing allows for the native reading of epigenetic modifications, distinguishing between 5-methylcytosine and 5-hydroxymethylcytosine on long reads. This technological shift significantly enhances data accuracy and simplifies workflows for high-throughput laboratories, driving the adoption of native sequencing platforms over complex chemical conversion protocols. Validating this demand for advanced direct sequencing capabilities, according to Oxford Nanopore Technologies plc, March 2025, in the 'Annual results for the year ended 31 December 2024', revenue from the PromethION product range, which supports high-output native methylation profiling, grew 55.8% to £75.9 million.

Simultaneously, the integration of artificial intelligence and machine learning is emerging as a critical trend to address the complexity of analyzing massive epigenetic datasets. As methylation profiling generates high-dimensional data, AI algorithms are increasingly deployed to identify novel biomarkers and predict patient outcomes with greater precision than manual bioinformatics pipelines can achieve. This computational advancement is rapidly monetizing as clinical providers seek intelligent diagnostics that combine genomic and clinical modalities to tailor precision medicine. Reflecting this growth in AI-driven genomic utility, according to Tempus AI, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the company reported that its Genomics segment revenue, which leverages AI-driven precision medicine models, reached $451.7 million for the full year 2024.

Key Market Players

  • Agilent Technologies, Inc.
  • Abcam Limited
  • Bio-Rad Laboratories, Inc
  • Illumina, Inc
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Pacific Biosciences of California, Inc.
  • Merck KGaA

Report Scope

In this report, the Global DNA Methylation Detection Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Methylation Detection Technology Market, By Technology

  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Sequencing
  • Other Technologies

DNA Methylation Detection Technology Market, By Application

  • Translational Research
  • Diagnostic Procedure

DNA Methylation Detection Technology Market, By Product

  • Consumables
  • Instruments
  • Software

DNA Methylation Detection Technology Market, By End User

  • Contract Research Organization (CRO)
  • Research and Academic Laboratories
  • Biopharmaceutical and Biotech Companies
  • Other End User

DNA Methylation Detection Technology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Methylation Detection Technology Market.

Available Customizations:

Global DNA Methylation Detection Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Methylation Detection Technology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Polymerase Chain Reaction (PCR), Microarray, Sequencing, Other Technologies)
    • 5.2.2. By Application (Translational Research, Diagnostic Procedure)
    • 5.2.3. By Product (Consumables, Instruments, Software)
    • 5.2.4. By End User (Contract Research Organization (CRO), Research and Academic Laboratories, Biopharmaceutical and Biotech Companies, Other End User)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America DNA Methylation Detection Technology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By Product
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States DNA Methylation Detection Technology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Product
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada DNA Methylation Detection Technology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Product
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico DNA Methylation Detection Technology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Product
        • 6.3.3.2.4. By End User

7. Europe DNA Methylation Detection Technology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By Product
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany DNA Methylation Detection Technology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Product
        • 7.3.1.2.4. By End User
    • 7.3.2. France DNA Methylation Detection Technology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Product
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom DNA Methylation Detection Technology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Product
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy DNA Methylation Detection Technology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Product
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain DNA Methylation Detection Technology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Product
        • 7.3.5.2.4. By End User

8. Asia Pacific DNA Methylation Detection Technology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By Product
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China DNA Methylation Detection Technology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Product
        • 8.3.1.2.4. By End User
    • 8.3.2. India DNA Methylation Detection Technology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Product
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan DNA Methylation Detection Technology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Product
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea DNA Methylation Detection Technology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Product
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia DNA Methylation Detection Technology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Product
        • 8.3.5.2.4. By End User

9. Middle East & Africa DNA Methylation Detection Technology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By Product
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia DNA Methylation Detection Technology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Product
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE DNA Methylation Detection Technology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Product
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa DNA Methylation Detection Technology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Product
        • 9.3.3.2.4. By End User

10. South America DNA Methylation Detection Technology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By Product
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil DNA Methylation Detection Technology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Product
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia DNA Methylation Detection Technology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Product
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina DNA Methylation Detection Technology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Product
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global DNA Methylation Detection Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abcam Limited
  • 15.3. Bio-Rad Laboratories, Inc
  • 15.4. Illumina, Inc
  • 15.5. Qiagen N.V.
  • 15.6. Thermo Fisher Scientific, Inc.
  • 15.7. F. Hoffmann-La Roche Ltd.
  • 15.8. Hologic, Inc.
  • 15.9. Pacific Biosciences of California, Inc.
  • 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer